Back to search results

EBV Specific T-Lymphocytes for EBV-Positive Lymphoma

This study is for patients with certain types of lymphoma (lymph gland cancer) or lymphoproliferative disease that are linked to the Epstein-Barr virus (EBV). Researchers are testing a treatment called EBV Specific T-Lymphocytes, which are special immune cells designed to find and fight cancer cells with EBV. You would donate blood to create these cells, which are then given back to you through an IV. Sometimes, standard chemotherapy medicines (cyclophosphamide and fludarabine) are given first. The main goal is to see how safe different doses of EBV Specific T-Lymphocytes are, specifically looking at any serious side effects within 28 days after treatment.

Study design
This is an interventional study with a planned enrollment of 52 participants. It is testing different doses of EBV Specific T-Lymphocytes.
What's involved
You will donate blood to create the treatment cells. You may receive chemotherapy medicines for 3 days, followed by an IV infusion of EBV Specific T-Lymphocytes, which takes 1 to 10 minutes.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for a total of 15 years to monitor for any long-term side effects of the gene transfer.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04664179

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

Recruiting
PHASE1All AgesInterventionalTreatment
Baylor College of Medicine
~52 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Dose Level 1A: 2 x 10^7 cells/m2Dose Level 2A: 6 x 10^7 cells/m2Dose Level 2B: 6 x 10^7 cells/m2Dose Level 3B: 2 x 10^8 cells/m2Dose Level 3A: 2 x 10^8 cells/m2Dose Level 1B: 2 x 10^7 cells/m2

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
1. Dose limiting toxicity rate (DLT) by Common Terminology Criteria for Adverse Events v5.0
Measured over 28 days post infusion

Conditions

EBV-Related Hodgkin Lymphoma
EBV-Related Lymphoproliferative Disorder
EBV Related Non-Hodgkin's Lymphoma

Explore related trials

Hodgkin's GranulomaNon-Hodgkin LymphomaT/NK-lymphoproliferative diseaseX-linked Lymphoproliferative Syndrome 1

Where it's being run

4 sites across 1 states
Texas4

Study leadership

  • Bilal Omer, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine

Who to contact

Bilal Omer, MD
[email protected]
832-824-6855
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • 1. Dose limiting toxicity rate (DLT) by Common Terminology Criteria for Adverse Events v5.028 days post infusion

    Dose-limiting toxicity is defined as any irreversible, life threatening or non-hematologic Grade 3-5 event considered to be primarily related to the EBVST infusion, with the exception of Grade 3-4 expected reactions such as fever and hypotension/ Grade 3-4 CRS toxicity persistent beyond 72 hours.